Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling

Amy C. Schefler; Alison Skalet; Scott C.N. Oliver; John Mason; Anthony B. Daniels; Katherina M. Alsina; Kristen M. Plasseraud; Federico A. Monzon; Brian Firestone

doi:10.2217/mmt-2020-0001

Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling

Amy C. Schefler, Alison Skalet, Scott C.N. Oliver, John Mason, Anthony B. Daniels, Katherina M. Alsina, Kristen M. Plasseraud, Federico A. Monzon, Brian Firestone

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.

Original language	English (US)
Pages (from-to)	17-25
Number of pages	9
Journal	Melanoma Management
Volume	7
Issue number	1
DOIs	https://doi.org/10.2217/mmt-2020-0001
State	Published - May 1 2020

Keywords

DecisionDx-UM
gene expression profiling
imaging
ocular melanoma
surveillance
uveal melanoma

ASJC Scopus subject areas

Oncology
Dermatology

Access to Document

10.2217/mmt-2020-0001

Cite this

@article{4117bdb647854301b445047ca2b565c8,

title = "Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling",

abstract = "Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.",

keywords = "DecisionDx-UM, gene expression profiling, imaging, ocular melanoma, surveillance, uveal melanoma",

author = "Schefler, {Amy C.} and Alison Skalet and Oliver, {Scott C.N.} and John Mason and Daniels, {Anthony B.} and Alsina, {Katherina M.} and Plasseraud, {Kristen M.} and Monzon, {Federico A.} and Brian Firestone",

note = "Publisher Copyright: {\textcopyright} 2020 Castle Biosciences, Inc.",

year = "2020",

month = may,

day = "1",

doi = "10.2217/mmt-2020-0001",

language = "English (US)",

volume = "7",

pages = "17--25",

journal = "Melanoma Management",

issn = "2045-0885",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling

AU - Schefler, Amy C.

AU - Skalet, Alison

AU - Oliver, Scott C.N.

AU - Mason, John

AU - Daniels, Anthony B.

AU - Alsina, Katherina M.

AU - Plasseraud, Kristen M.

AU - Monzon, Federico A.

AU - Firestone, Brian

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.

AB - Aim: The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort. Patients & methods: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected. Results: A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance. Conclusion: Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.

KW - DecisionDx-UM

KW - gene expression profiling

KW - imaging

KW - ocular melanoma

KW - surveillance

KW - uveal melanoma

UR - http://www.scopus.com/inward/record.url?scp=85095777319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095777319&partnerID=8YFLogxK

U2 - 10.2217/mmt-2020-0001

DO - 10.2217/mmt-2020-0001

M3 - Article

AN - SCOPUS:85095777319

SN - 2045-0885

VL - 7

SP - 17

EP - 25

JO - Melanoma Management

JF - Melanoma Management

IS - 1

ER -

Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this